首页>
外文期刊>american journal of hematology
>Pharmacokinetics and tolerance of intravenous and intramuscular recombinant alpha2interferon in patients with malignancies
【24h】
Pharmacokinetics and tolerance of intravenous and intramuscular recombinant alpha2interferon in patients with malignancies
展开▼
机译：Pharmacokinetics and tolerance of intravenous and intramuscular recombinant alpha2interferon in patients with malignancies
AbstractFifteen patients with advanced hematopoietic and other malignancies were treated with recombinant DNA produced Alpha2Interferon (IFN) (Schering) by intravenous (IV) and intramuscular (IM) routes at weekly intervals in escalating doses from 1 × 106IU to 100 × 106IU in order to determine the tolerance and pharmacokinetics. The most common side effects included fever, chills, myalgia, and arthralgia. At doses of 60 × 106or above, severe but reversible hypotension was observed in five patients receiving interferon by intravenous route. Patients receiving interferon by intramuscular route had fever, chills, and myalgias but did not develop hypotension at the same dosage. Two patients with non‐Hodgkin lymphoma showed objective evidence of regression. Our data suggest a biphasic pattern of elimination with terminal half‐life ranging from 1.9 to 2.9 hours and peak titer of 16,000 units and under for IV interferon, and terminal half‐life of 6 hours with peak titers of 600 units for intramuscular interferon. However, interpatient variability precludes a definite conclusion.Although the areas under the serum concentration vs time curves were similar, the intravenous route provided higher but unsustained levels of interferon than the intramuscul
展开▼
